Close
Achema middle east
swop processing & packaging

CMIC Group Establishes a New Biologic Contract Development and Manufacturing Business in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

CMIC HOLDINGS Co., Ltd. announced the establishment of CMIC BIO Co., Ltd. (hereafter CMIC BIO), a fully-owned subsidiary that offers Contract Development and Manufacturing Organization (hereinafter CDMO) services for biopharmaceutical drug substance. CMIC Bio has a single-use facility in Shizuoka, Japan for process development and GMP manufacturing of antibody drug using mammalian cell line. The facility will be in full-scale operation from October 2020.

In recent years, the biopharmaceutical-related market has continued to expand, and companies from other industries other than pharmaceutical companies have entered the market. Each company emphasizes the speed to acquire POC in order to quickly identify the development compound, and at the same time, the need for multi-product, small-volume production is rising. Given this situation, it is difficult to produce all of the development products in-house, and an increasing number of cases utilize outsourcing.

For the period from April 2014 to September 2019, CMIC JSR Biologics Co., Ltd. participated in the Japan Science and Technology Agency’s Program (NexTEP) (Project name: design and manufacturing technology of multispecific antibodies). Research has been conducted in the fields of manufacturing and quality control of biotechnology-derived pharmaceuticals, with a focus on the manufacturing process development of bispecific antibodies. Based on these experiences, we establish CMIC Bio and start the biopharmaceutical drug substances CDMO business.” At CMIC Bio, we have personnel with abundant experience at pharmaceutical companies and have strengths in GMP API manufacturing bases in Japan to assist in accelerating the development speed of biopharmaceuticals.” Commented Hiroshi Kosaku, President of CMIC Pharmaceutical Sciences.

“CMIC Group will provide end to end solutions from non-clinical testing, running clinical trial, GMP manufacturing of biopharmaceuticals to the commercialization and post market.”

About CMIC Group
CMIC Group was founded in 1992 as the first Contract Research Organization (CRO) in Japan. Today CMIC Group is the largest clinical CRO in Japan with global footprint, providing comprehensive services in drug development, clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge drug development and manufacturing needs in the US, Europe, Japan and broader Asia. CMIC Group has over 7,000 employees and 25 sites globally.

Latest stories

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »